Radius Health is a biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer. The company was founded in 2003 and is based in Waltham, Massachusetts.
Radius Health, Inc. (“Radius” or the “Company”) (RDUS), today announced that its partner, Teijin Pharma Limited, has submitted a New Drug Application for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at high risk for fractures. The application is based on the positive results of the Phase III clinical study of abaloparatide-SC in Japan which included osteoporosis patients at high risk for fracture. “We are pleased that our partner Teijin has achieved this significant milestone toward the potential introduction of abaloparatide as a new treatment option for osteoporosis patients,” stated Kelly Martin, CEO of Radius.
Before we begin, I'd like to remind you with our Safe Harbor slide that we'll have some forward-looking statements and include non-GAAP financial measures in our presentation today. Any forward-looking statements represent our views as of today only.